Diabetic Retinopathy
Pipeline by Development Stage
Drug Modality Breakdown
Ophthalmology is a $3.7B market with a mature, consolidating portfolio dominated by glaucoma treatments and emerging corneal/retinal therapies.
Key Trends
- Glaucoma therapeutics (prostaglandin analogs, adrenergic agents) represent 60%+ of spending but face patent cliffs 2028-2034
- Innovative mechanisms (NGF agonists, LFA-1 antagonists, RTKIs) gaining traction in dry eye and retinal disease segments
- Heavy trial activity (2,656 total) skewed toward Phase 4 (369) and Phase 3 (442), indicating mature clinical development landscape
Career Verdict
Ophthalmology offers stable mid-career opportunities with strong Commercial and Medical Affairs salaries, but limited innovation catalysts and significant patent cliff risk warrant careful timing of entry.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LUMIGAN (Bimatoprost) | AbbVie | $697M | 19% | LOE_APPROACHING | Declining | |
| 2 | OXERVATE (Cenegermin-BKBJ) | Unspecified | $493M | 13% | PEAK | Stable | |
| 3 | XIIDRA (Lifitegrast) | Bausch + Lomb | $473M | 13% | PEAK | Stable | 7.6yr |
| 4 | INLYTA (Axitinib) | Pfizer | $467M | 13% | PEAK | Growing | 11.2yr |
| 5 | HUMIRA (Adalimumab) | AbbVie | $258M | 7% | LOE_APPROACHING | Declining |
Drug Class Breakdown
mature, losing exclusivity
peak growth in corneal disease
sustained peak sales
expanding in retinal indications
mature, multiple LOE approaching
mature, losing exclusivity
mature immunology approach
Career Outlook
StableOphthalmology offers predictable mid-career growth with strong Commercial ($158K) and Medical Affairs ($247K) compensation but faces structural headwinds: patent cliffs 2028-2034 eliminate $97M in revenue, glaucoma franchise maturity limits blockbuster potential, and modest trial volume (2,656) signals incremental R&D expansion. Best suited for professionals seeking stable roles in established therapeutic areas rather than disruptive innovation.
Breaking In
Enter via Clinical Operations or Commercial analyst roles at CROs (Syneos 210 jobs) or large diagnostics players (Labcorp 904) to build domain expertise before targeting pharma MSL/Medical Affairs positions.
For Experienced Professionals
Experienced professionals should prioritize Medical Affairs and Market Access roles leveraging mature market knowledge; avoid product-specific expertise in glaucoma due to patent cliff concentration, and consider adjacent areas (retinal, corneal) where innovation catalysts remain.
In-Demand Skills
Best For
Hiring Landscape
Ophthalmology hiring (3,202 jobs) is distributed across diagnostics/devices (Labcorp 904, Abbott 348) and pharma commercial functions rather than concentrated in R&D. Top pharmaceutical employers (Pfizer 60, AstraZeneca 100, Regeneron 168) show modest pharma-specific headcount relative to market size, suggesting outsourced CRO and distributor dependency. Medical Affairs ($247K avg salary) commands premium compensation, signaling high barrier to entry but strong mid-career upside.
Top Hiring Companies
By Department
Clinical Operations and Commercial roles offer entry-level stability ($150K-$158K); Medical Affairs commands premium salaries ($247K) but requires advanced credentials; limited R&D hiring (207 jobs) suggests constrained innovation investment.
Competitive Landscape
33 companies ranked by most advanced pipeline stage
+3 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 8,256 patients across 50 trials
Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy
Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial
Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab
A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon®
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
Fenofibrate for Prevention of DR Worsening
Anti-VEGF Treatment for Prevention of PDR/DME
Macular Edema Incidence/Severity Reduction With Nevanac
Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
Anecortave Acetate Risk Reduction Trial (AART)
Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
Anecortave Acetate Risk-Reduction Trial (AART)
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
Anecortave Acetate Risk-Reduction Trial (AART)
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension
A Multi-Dose Study With a Treatment for Open-Angle Glaucoma
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
Evaluation of RC28-E Injection in Diabetic Retinopathy
Non-proliferative Diabetic Retinopathy Treated With Runcaciguat
A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement
A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension
Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema
Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma
Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema
Anecortave Acetate in Patients With Open-angle Glaucoma
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.
Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)
Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).
Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).
Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)
Anecortave Acetate Versus Placebo in AMD Patients Following PDT
A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration
A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment
Related Jobs in Ophthalmology
Field Reimbursement Manager (FRM), Ophthalmology – New Jersey
Director, Contract Strategy
Medical Director - Ophthalmology
Medical Specialist II - Ophthalmology (Iowa/Western Illinois)
Associate Director, Omnichannel Customer Experience, Consumer Marketing (Ophthalmology)
Medical Specialist II - Ophthalmology - Naples, Miami, Ft. Myers
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.